A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells

By              

Oncology Reports, Vol. 30, Iss. 2, 2013-01 ,pp. : 863-869

Spandidos Publications

Access to resources Recommend Favorite

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

By                    

International Journal of Oncology, Vol. 45, Iss. 3, 2014-01 ,pp. : 1027-1035

Spandidos Publications

Access to resources Recommend Favorite

PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts

By Choo Edna   Ng Chee   Berry Leanne   Belvin Marcia   Lewin-Koh Nicholas   Merchant Mark   Salphati Laurent  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 133-143

Springer Publishing Company

Access to resources Recommend Favorite

PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas

By            

International Journal of Oncology, Vol. 48, Iss. 1, 2016-01 ,pp. : 253-260

Spandidos Publications

Access to resources Recommend Favorite

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer

By        

International Journal of Oncology, Vol. 43, Iss. 5, 2013-01 ,pp. : 1627-1635

Spandidos Publications

Access to resources Recommend Favorite